Med24
clinical-research 19. 10. 2026 • 2 min read • ClinicalTrials.gov (Saglik Bilimleri Universitesi)

Erectile and Ejaculatory Function in Men With and Without a History of Coronary Revascularization: A Cross-Sectional Comparative Study

This observational, cross-sectional study aims to compare erectile and ejaculatory function between men with a history of coronary revascularization and men without known coronary artery disease. The study included 135 adult male participants, including 66 men who had previously undergone percutaneous coronary...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

An observational, cross-sectional study compared erectile and ejaculatory function in men with and without a history of coronary revascularization. The study included 135 adult male participants, comprising 66 men who had undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and 69 men without known coronary artery disease.

Key Clinical Findings

Erectile function was evaluated using the Sexual Health Inventory for Men (SHIM), premature ejaculation symptoms using the Premature Ejaculation Diagnostic Tool (PEDT), and ejaculatory function using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD). Ejaculation latency was also self-reported. The primary objective was to investigate the association between previous coronary revascularization and erectile function. Secondary objectives included comparing premature ejaculation symptoms, ejaculatory function, and ejaculation latency between the two groups. Participants in the revascularization group were evaluated at least one month after their most recent PCI or CABG procedure. Assessments utilized the SHIM, PEDT, and MSHQ-EjD.

Sponsored content

Study Design and Measurements

Between-group comparisons were performed using appropriate statistical tests.

Original Scientific Source
ClinicalTrials.gov (Saglik Bilimleri Universitesi)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement